B. Riley kept a Buy rating on Corbus Pharmaceuticals (CRBP) with a $28 price target following a transfer of coverage. The firm believes the company has a “promising” next-generation nectin-4 antibody drug conjugate with the potential to disrupt treatment paradigms in two “underserved” solid tumor types: head and neck and cervical cancer.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- Corbus announces presentation of dose expansion Phase 1/2 data for CRB-701
- Corbus Pharmaceuticals initiates MAD portion of its Phase 1 trial for CRB-913
- Corbus says first patient dosed in PD-1 combo arm of Phase 1 study of CRB-701
- Corbus Pharmaceuticals: Strategic Positioning and Promising Pipeline Drive Buy Rating
- Buy Rating for Corbus Pharmaceuticals’ CRB-701: Promising Efficacy and Safety in Oncology